Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Langdon

Showing results (121-130 of 180) with videos related to

Pageof 18
Sort By:
British Journal of Cancer|December 18, 2001
Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancerF McPhillips, P Mullen, B P Monia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1995
Pharmacokinetics, metabolism, tissue and tumour distribution of the neuropeptide growth factor antagonist [Arg6, D-Trp7,9, NmePhe8]- substance P(6-11) in nude mice bearing the H69 small-cell lung cancer xenograftJ Cummings, A J MacLellan, D A Jones, et al.
Gynecologic Oncology|August 6, 2013
Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancerPeter A Argenta, Inhwa Um, Charlene Kay, et al.
Cancer Chemotherapy and Pharmacology|October 15, 1998
Growth-inhibitory effects of the synthetic retinoid CD437 against ovarian carcinoma models in vitro and in vivoS P Langdon, G J Rabiasz, A A Ritchie, et al.
Cancer Treatment Reviews|October 16, 2012
New strategies for targeting the hypoxic tumour microenvironment in breast cancerCarol Ward, Simon P Langdon, Peter Mullen, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft modelS P Langdon, A J Crew, A A Ritchie, et al.
Exploration of Targeted Anti-Tumor Therapy|September 1, 2022
The impact of tumour pH on cancer progression: strategies for clinical interventionCarol Ward, James Meehan, Mark E Gray, et al.
Endocrine-Related Cancer|December 13, 2006
Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer modelsBarbara Kuske, Catherine Naughton, Kate Moore, et al.
British Journal of Cancer|June 9, 1999
Regulation and function of the extracellular matrix protein tenascin-C in ovarian cancer cell linesK E Wilson, J M Bartlett, E P Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 1996
Cyclic adenosine 3',5'-monophosphate-binding proteins in human ovarian cancer: correlations with clinicopathological featuresB J Simpson, A D Ramage, M J Hulme, et al.
Pageof 18

Showing results (121-130 of 180) with videos related to

Sort By:
Pageof 18
British Journal of Cancer|December 18, 2001
Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancerF McPhillips, P Mullen, B P Monia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1995
Pharmacokinetics, metabolism, tissue and tumour distribution of the neuropeptide growth factor antagonist [Arg6, D-Trp7,9, NmePhe8]- substance P(6-11) in nude mice bearing the H69 small-cell lung cancer xenograftJ Cummings, A J MacLellan, D A Jones, et al.
Gynecologic Oncology|August 6, 2013
Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancerPeter A Argenta, Inhwa Um, Charlene Kay, et al.
Cancer Chemotherapy and Pharmacology|October 15, 1998
Growth-inhibitory effects of the synthetic retinoid CD437 against ovarian carcinoma models in vitro and in vivoS P Langdon, G J Rabiasz, A A Ritchie, et al.
Cancer Treatment Reviews|October 16, 2012
New strategies for targeting the hypoxic tumour microenvironment in breast cancerCarol Ward, Simon P Langdon, Peter Mullen, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft modelS P Langdon, A J Crew, A A Ritchie, et al.
Exploration of Targeted Anti-Tumor Therapy|September 1, 2022
The impact of tumour pH on cancer progression: strategies for clinical interventionCarol Ward, James Meehan, Mark E Gray, et al.
Endocrine-Related Cancer|December 13, 2006
Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer modelsBarbara Kuske, Catherine Naughton, Kate Moore, et al.
British Journal of Cancer|June 9, 1999
Regulation and function of the extracellular matrix protein tenascin-C in ovarian cancer cell linesK E Wilson, J M Bartlett, E P Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 1996
Cyclic adenosine 3',5'-monophosphate-binding proteins in human ovarian cancer: correlations with clinicopathological featuresB J Simpson, A D Ramage, M J Hulme, et al.
Pageof 18